Company

Sylentis

As of the edition of 20 October 2026, Sylentis runs 4 drugs; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet2
Status not established2
Total4

Where it needs a new molecule

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
TargetRoute
TRPV1 Transient receptor potential cation channel subfamily V member 1Route A
ADRB2 Beta-2 adrenergic receptorRoute A

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Eye: 10 trials led